Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 11/20 | 1.00 |
| ▸ | RELA | Q04206 | 4/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.68 |
| ▸ | APP | P05067 | 1/20 | 0.65 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14401253 | 1.00 | NFE2L2 (1.00) | NFE2L2RELAPTGS1APPTRPA1 | |
| SCHEMBL5490783 | 1.00 | NFE2L2 (1.00) | NFE2L2RELAPTGS1APPTRPA1 | |
| SCHEMBL21030080 | 0.87 | NFE2L2 (1.00) | NFE2L2RELAPTGS1 | |
| SCHEMBL10338773 | 0.87 | RELA (0.85) | NFE2L2RELAPTGS1APPTRPA1 | |
| SCHEMBL18240792 | 0.86 | NFE2L2 (0.75) | NFE2L2RELAPTGS1APPTRPA1 | |
| SCHEMBL9849735 | 0.84 | NFE2L2 (0.91) | NFE2L2RELAPTGS1 | |
| SCHEMBL6461623 | 0.83 | NFE2L2 (0.74) | NFE2L2RELAPTGS1TRPA1 | |
| SCHEMBL699631 | 0.83 | RELA (1.00) | NFE2L2RELAAPPTRPA1 | |
| SCHEMBL13778224 | 0.83 | RELA (1.00) | NFE2L2RELAAPPTRPA1 | |
| SCHEMBL6470139 | 0.83 | NFE2L2 (0.74) | NFE2L2RELAPTGS1TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8980954-B2 | Substituted cis- and trans-stilbenes as therapeutic agents | STC.UNM (US) | 2015-03-17 | — | — | US | claimed |
| US-20220023172-A1 | COSMETIC COMPOSITIONS AND METHODS OF USE | TRUJILLO KRISTINA (US) | 2022-01-27 | — | — | US | disclosed |
| US-20200397676-A1 | COSMETIC COMPOSITIONS AND METHODS OF USE | K&K BIOTECH (US) | 2020-12-24 | — | — | US | disclosed |
| WO-2020112998-A1 | COSMETIC COMPOSITIONS AND METHODS OF USE | STC.UNM (US) | 2020-06-04 | — | — | WO | disclosed |
| US-20190160021-A1 | Substituted Stilbenes as Inhibitors of NF-kappaB and Activators of Nrf2 | STC UNM (US) | 2019-05-30 | — | — | US | disclosed |
| US-9925153-B2 | Therapeutic agents for skin diseases and conditions | STC.UNM (US) | 2018-03-27 | — | — | US | disclosed |
| US-9925153-B2 | Therapeutic agents for skin diseases and conditions | STC.UNM (US) | 2018-03-27 | — | — | US | disclosed |
| US-20160287531-A1 | THERAPEUTIC AGENTS FOR SKIN DISEASES AND CONDITIONS | STC.UNM | 2016-10-06 | — | — | US | disclosed |
| US-20160287531-A1 | THERAPEUTIC AGENTS FOR SKIN DISEASES AND CONDITIONS | STC.UNM | 2016-10-06 | — | — | US | disclosed |
| WO-2015085143-A2 | THERAPEUTIC AGENTS FOR SKIN DISEASES AND CONDITIONS | STC.UNM (US) | 2015-06-11 | — | — | WO | disclosed |
| WO-2015085143-A2 | THERAPEUTIC AGENTS FOR SKIN DISEASES AND CONDITIONS | STC.UNM (US) | 2015-06-11 | — | — | WO | disclosed |
| US-8980954-B2 | Substituted cis- and trans-stilbenes as therapeutic agents | STC.UNM (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980954-B2 | Substituted cis- and trans-stilbenes as therapeutic agents | STC.UNM (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980954-B2 | Substituted cis- and trans-stilbenes as therapeutic agents | STC.UNM (US) | 2015-03-17 | — | — | US | disclosed |
| US-20140271470-A1 | TARGETED THERANOSTICS FOR METASTATIC PROSTATE CANCER | THE REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2014-09-18 | — | — | US | disclosed |
| US-20130178536-A1 | SUBSTITUTED CIS- AND TRANS-STILBENES AS THERAPEUTIC AGENTS | STC.UNM (US) | 2013-07-11 | — | — | US | disclosed |
| US-20070249647-A1 | Substituted CIS- and trans-stilbenes as therapeutic agents | REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2007-10-25 | — | — | US | disclosed |
| US-20070249647-A1 | Substituted CIS- and trans-stilbenes as therapeutic agents | REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2007-10-25 | — | — | US | disclosed |
| US-20070249647-A1 | Substituted CIS- and trans-stilbenes as therapeutic agents | REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190160021-A1 | Substituted Stilbenes as Inhibitors of NF-kappaB and Activators of Nrf2 | NFKBIA, NFE2L2, NFKB2 | NFE2L2 2/4885RELA 4/4885PTGS1 312/4885 |
| US-20160287531-A1 | THERAPEUTIC AGENTS FOR SKIN DISEASES AND CONDITIONS | CUTA, TSLP, ELANE | NFE2L2 696/4885RELA 29/4885PTGS1 1081/4885 |
| US-20220023172-A1 | COSMETIC COMPOSITIONS AND METHODS OF USE | NFKBIA, IKBKB, NFKB2 | NFE2L2 9/4885RELA 32/4885PTGS1 263/4885 |
| US-20070249647-A1 | Substituted CIS- and trans-stilbenes as therapeutic agents | TGFB1, VHL, TMSB10 | NFE2L2 68/4885RELA 12/4885PTGS1 26/4885 |
| US-20140271470-A1 | TARGETED THERANOSTICS FOR METASTATIC PROSTATE CANCER | KLK3, ACP3, FOLH1 | NFE2L2 902/4885RELA 524/4885PTGS1 683/4885 |
| US-20130178536-A1 | SUBSTITUTED CIS- AND TRANS-STILBENES AS THERAPEUTIC AGENTS | PSEN1, TERT, PSEN2 | NFE2L2 63/4885RELA 10/4885PTGS1 83/4885 |
| US-20200397676-A1 | COSMETIC COMPOSITIONS AND METHODS OF USE | KEAP1, NFE2L2, NQO1 | NFE2L2 2/4885RELA 6/4885PTGS1 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.